亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 5756: Preclinical evaluation of BH4601, a novel tetravalent PD-L1 and B7H3 bispecific antibody-drug conjugate (ADC) with Topo1 inhibitor for the treatment of solid tumors

作者
Jun Wang,Pengfei Rong,Jing Wang,Yang Liu,Mengrui Zhao,Jie Feng,Lijuan Li,Yue Wang,Aihong Zhang,Dongyang Li,Hongjuan Zhang,Jingmei Cai,Xiaochun Li,Jiangcheng Xu,Jiawang Liu,Hui Ding,Fangxing Ouyang,Kyoungwoo Lee
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 5756-5756
标识
DOI:10.1158/1538-7445.am2026-5756
摘要

Abstract PD-L1 and B7-H3, members of the B7 superfamily, are frequently overexpressed across various tumor types. While antibody-drug conjugates (ADCs) targeting either PD-L1 or B7-H3 individually have demonstrated modest clinical efficacy, their co-expression in multiple malignancies presents a compelling rationale for dual-targeting strategies. This bispecific approach broadens the scope of tumor targeting and simultaneously alleviates T-cell suppression, potentially leading to enhanced therapeutic efficacy. The dual-targeting strategy addresses the compensatory upregulation observed between these targets—where suppression of B7-H3 leads to PD-L1 upregulation, and vice versa. A novel bispecific antibody concurrently targeting PD-L1 and B7-H3 was conjugated with a topoisomerase I inhibitor (XYD-295) and BH4601 was generated. In vitro evaluations revealed that BH4601 exhibits excellent target binding and internalization activities, as well as potent PD-1/PD-L1 blockade. Effective tumor control was demonstrated in multiple in vivo models, accompanied by significant T-cell activation. All animals remained well-tolerated at efficacious dose levels. By simultaneously engaging both PD-L1 and B7H3 pathways, BH4601 achieves enhanced tumor-specific distribution and efficient tumor cell internalization, potentially improving both efficacy and safety profiles compared to its parental ADCs. Citation Format: Jun Wang, Pengfei Rong, Jing Wang, Yang Liu, Mengrui Zhao, Jie Feng, Lijuan Li, Yue Wang, Aihong Zhang, Dongyang Li, Hongjuan Zhang, Jingmei Cai, Xiaochun Li, Jiangcheng Xu, Jiawang Liu, Hui Ding, Fangxing Ouyang, Kyoungwoo Lee. Preclinical evaluation of BH4601, a novel tetravalent PD-L1 and B7H3 bispecific antibody-drug conjugate (ADC) with Topo1 inhibitor for the treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5756.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被u855744采纳,获得10
1秒前
科研通AI6.3的应助被u855744采纳,获得10
3秒前
科研通AI6.3的应助被u264877采纳,获得10
3秒前
科研通AI6.2的应助被u855744采纳,获得10
5秒前
科研通AI6.3的应助被u855744采纳,获得10
5秒前
科研通AI6.2的应助被u264877采纳,获得10
8秒前
科研通AI6.3的应助被u264877采纳,获得10
9秒前
风吹麦浪的应助被u583484采纳,获得10
9秒前
科研通AI6.3的应助被u264877采纳,获得10
13秒前
漂亮的新梅完成签到,获得积分10
23秒前
七七完成签到 ,获得积分10
30秒前
忧郁的数据线关注了科研通微信公众号
36秒前
40秒前
syvshc的应助被u721406采纳,获得10
41秒前
u588294驳回了852的应助
43秒前
44秒前
46秒前
遇上就这样吧给u266829的求助进行了留言
48秒前
顺利手链完成签到,获得积分10
49秒前
生动的昊焱完成签到,获得积分10
57秒前
阿切尔代的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
吴彦祖发布了新的文献求助10
1分钟前
大胆醉卉完成签到,获得积分10
1分钟前
吴彦祖完成签到,获得积分10
1分钟前
识时务这也完成签到,获得积分10
1分钟前
烂漫琳完成签到,获得积分10
1分钟前
张哩哩完成签到,获得积分10
1分钟前
1分钟前
Jason完成签到,获得积分10
1分钟前
1分钟前
Jason发布了新的文献求助10
1分钟前
今后的应助被生锈的铁片采纳,获得10
2分钟前
务实寒烟完成签到,获得积分10
2分钟前
Huaaaaay完成签到 ,获得积分10
2分钟前
合适的千秋完成签到,获得积分10
2分钟前
直率水儿完成签到,获得积分10
2分钟前
2分钟前
syvshc的应助被u488353采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185144
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782640
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558762
邀请新用户注册赠送积分活动 2481206